GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ABBV
The stock price of biopharmaceutical company AbbVie has long been dependent on its blockbuster drug, Humira. Today, the chart reflects the company's ability to diversify its drug portfolio and successfully launch new drugs, offsetting the loss of patent protection for its flagship product.
Share prices of companies in the market segment - Pharma holding
AbbVie is a pharmaceutical giant whose portfolio is divided into immunology (Humira), oncology, and aesthetic medicine (Botox) segments. We classify the company as part of the Pharma holdings sector, and the chart below shows the overall dynamics of the entire large drug manufacturing industry.
Broad Market Index - GURU.Markets
AbbVie is a major biopharmaceutical company known for its blockbusters in immunology and oncology. Its significant market capitalization earns it a prominent place in the GURU.Markets index. The chart below represents the entire market. See how AbbVie shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ABBV - Daily change in the company's share price ABBV
The daily price change for AbbVie, a major biopharmaceutical company, demonstrates its sensitivity to patent news and research results. While the chart of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma holding
AbbVie is one of the pharmaceutical industry's giants. This chart reflects the average daily volatility of the entire sector, influenced by clinical trial news. It serves as a benchmark for comparing the stability of a company heavily dependent on a single blockbuster with the overall industry backdrop.
Daily change in the price of a broad market stock, index - GURU.Markets
AbbVie is a major biopharmaceutical company known for its blockbusters. The pharmaceutical sector may operate by its own rules, but shares of such giants are still subject to overall market trends. The chart below shows overall market volatility, providing context for assessing AbbVie's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ABBV
Over the past year, AbbVie has continued to demonstrate the strength of its immunology and oncology portfolio, seeking to offset the loss of exclusivity for its blockbuster drug Humira. The chart below shows how investors assessed the success of new products and the company's ability to sustain long-term growth.
Annual dynamics of market capitalization of the market segment - Pharma holding
AbbVie, a leading biopharmaceutical company, is facing the challenge of losing exclusivity for its blockbuster drug Humira. Its success depends on its ability to compensate for this loss with new drugs. The stock performance chart, relative to its sector, clearly shows how confident investors are in its new product line and future growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
AbbVie, the biopharmaceutical company known for its blockbuster drug Humira, exhibits dynamism dependent on the life cycle of its drugs. Investors value its ability to replace revenue from older drugs with new developments. This makes it less dependent on general economic cycles but sensitive to news from the world of medicine and patent law.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ABBV
AbbVie's monthly performance reveals how the pharmaceutical company manages the life cycle of its products. Fluctuations on the chart reflect investor concerns about the patent expiration of its blockbuster drug, Humira, and, conversely, the success of new drugs designed to offset lost revenue.
Monthly dynamics of market capitalization of the market segment - Pharma holding
What you see here is the dynamics of the entire pharmaceutical sector, where AbbVie is one of the largest players. Its movements reflect general trends, such as the expiration of patents on blockbusters and the need for new developments. This is the backdrop against which AbbVie sought new sources of growth after the Humira era.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
This chart reflects overall market sentiment. For AbbVie, a large pharmaceutical company, this is the backdrop. Its movements are typically less volatile than the market, demonstrating the defensive nature of its business, based on patented drugs and stable cash flows.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ABBV
Shares of AbbVie, the biopharmaceutical company known for its blockbuster drug Humira, fluctuate weekly, driven by news about patent protections, new drug trial results, and sales forecasts. This chart shows how investors assess the company's ability to compensate for the loss of exclusivity for its key drugs.
Weekly dynamics of market capitalization of the market segment - Pharma holding
As a major biopharmaceutical company, AbbVie often follows the industry's overall trends. However, its heavy reliance on the blockbuster Humira and its success in introducing new drugs create its own news agenda. This chart helps us understand whether the company is outperforming the industry average through innovation or lagging behind due to patent risks.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
AbbVie, the owner of one of the world's best-selling drugs, Humira, is currently undergoing a transformation. The market is closely monitoring whether new drugs will offset the loss of exclusivity. The chart below shows how this uncertainty affects stock volatility relative to the market.
Market capitalization of the company, segment and market as a whole
ABBV - Market capitalization of the company ABBV
AbbVie's market capitalization tells the story of how the market values a pharmaceutical company dependent on a single blockbuster. A significant portion of its value was built on the success of Humira. The chart shows how investors reacted to the news of the loss of patent protection and how they assess the company's ability to find new growth drivers through new developments and acquisitions.
ABBV - Share of the company's market capitalization ABBV within the market segment - Pharma holding
AbbVie, a spinoff from Abbott, became a pharmaceutical giant thanks to the blockbuster Humira. Its significant market share reflects its success in immunology and oncology. The company's market capitalization demonstrates its ability to generate massive revenues from key drugs and develop new ones.
Market capitalization of the market segment - Pharma holding
This chart reflects the trillion-dollar value of the global pharmaceutical industry. AbbVie, spun off from Abbott, became one of its titans thanks to its blockbuster drug Humira. The sector's dynamics currently reflect the race for new breakthrough drugs, and AbbVie is actively participating in this race to strengthen its leadership position.
Market capitalization of all companies included in a broad market index - GURU.Markets
AbbVie's value is largely based on the success of one of the best-selling drugs in history. It's an example of how a single pharmaceutical patent can create a giant company. The chart below illustrates the enormous market share a successful biopharmaceutical innovation can capture.
Book value capitalization of the company, segment and market as a whole
ABBV - Book value capitalization of the company ABBV
AbbVie's book value is a tangible reflection of its pharmaceutical strength, built on the production capacity for blockbusters like Humira and massive investments in new drug development. The chart shows how the company uses revenue from its key drugs to grow its patent portfolio and expand its manufacturing base.
ABBV - Share of the company's book capitalization ABBV within the market segment - Pharma holding
AbbVie's success is underpinned by massive investments in physical infrastructure. The chart shows the company's share of the pharmaceutical industry's tangible assets: cutting-edge R&D centers where blockbusters are born, and high-tech factories capable of producing complex biologics on an industrial scale.
Market segment balance sheet capitalization - Pharma holding
Pharmaceuticals, as the chart shows, is a capital-intensive industry. AbbVie is a prime example. Its success is based on billions of dollars invested in R&D to create blockbusters and high-tech factories to produce complex biological drugs. It's a knowledge- and capital-intensive business.
Book value of all companies included in the broad market index - GURU.Markets
AbbVie is a leader in the biopharmaceutical industry. Its significant book value reflects its advanced manufacturing facilities and, more importantly, its portfolio of blockbuster patents, such as Humira. This provides the material and intellectual foundation for the development of breakthrough treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ABBV
AbbVie's real assets are its factories and laboratories. But its market valuation has long been tied to a single asset: the patent for the blockbuster drug Humira. The chart shows how this ratio changes depending on whether investors believe the company can find new sources of growth after losing exclusivity.
Market to book capitalization ratio in a market segment - Pharma holding
AbbVie is a pharmaceutical company whose market capitalization has long depended on the blockbuster drug Humira. Now the market is assessing its ability to replace these revenues with new drugs. This chart shows how investor expectations regarding the future of the drug portfolio and R&D success are creating a gap between the market valuation and the book value of assets.
Market to book capitalization ratio for the market as a whole
AbbVie is a biopharmaceutical company known for blockbusters like Humira. Its value is closely tied to the patent lifecycle of its key drugs and the success of new developments. This chart shows the average market valuation, against which AbbVie's premium reflects the profitability of its current pipeline and expectations for future drugs.
Debts of the company, segment and market as a whole
ABBV - Company debts ABBV
AbbVie's debt history is inextricably linked to its strategic M&A deals, most notably the acquisition of Allergan. The company used debt as the primary tool to finance this transformational transaction, dramatically increasing its scale. This chart clearly demonstrates how debt can be used to fundamentally reshape a business.
Market segment debts - Pharma holding
AbbVie, one of the largest pharmaceutical companies, was heavily dependent on its blockbuster drug Humira. To mitigate the risks, the company completed a mega-deal to acquire Allergan, financing it largely with debt. This chart clearly demonstrates how an M&A strategy can dramatically alter a company's debt profile and the risks this entails.
Market debt in general
AbbVie is a biopharmaceutical company known for its blockbuster drug, Humira. Its reliance on a single drug forces the company to invest heavily in new developments and make acquisitions to diversify its portfolio. This chart helps understand how AbbVie's M&A strategy and associated debt load compare to the overall corporate debt situation.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ABBV
AbbVie, spun off from Abbott Labs, owes much of its success to the blockbuster drug Humira. This chart shows how the company uses debt to reduce its reliance on one drug by acquiring other companies with promising developments. The high debt load is the price of diversification and an attempt to secure future growth after patent loss.
Market segment debt to market segment book capitalization - Pharma holding
AbbVie is a large biopharmaceutical company whose success depends on blockbusters and continuous investment in the development of new drugs. This chart allows us to evaluate its financial strategy. It shows how aggressively the company uses debt to fund research and acquisitions compared to the overall financial strength of the pharmaceutical industry.
Debt to book value of all companies in the market
AbbVie is a major biopharmaceutical company whose growth was partially fueled by its massive, debt-financed acquisition of Allergan. This chart clearly illustrates the impact of that deal. It compares the company's high debt load to the average level for the economy, reflecting its aggressive growth strategy through M&A.
P/E of the company, segment and market as a whole
P/E - ABBV
For AbbVie, one of the largest biopharmaceutical companies, this chart reflects a complex balance. On the one hand, the company has highly profitable drugs. On the other, there's the constant risk of patent expiration. The P/E ratio reflects investors' confidence in the company's R&D team's ability to create new blockbusters to replace older ones.
P/E of the market segment - Pharma holding
AbbVie is a large biopharmaceutical company known for its blockbuster immunology and oncology products. Its reliance on a few key drugs creates certain risks. This chart shows the average valuation for the pharmaceutical industry, allowing investors to compare how the market views the risks and prospects of AbbVie's drug portfolio relative to its competitors.
P/E of the market as a whole
AbbVie is a biopharmaceutical company known for blockbusters like Humira. Its valuation is determined by the patent lifecycle of its key drugs and the success of new developments. While this chart illustrates the general ebb and flow of the market, for AbbVie, clinical trials and regulatory decisions are far more important, as they could change its fate overnight.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ABBV
The valuation of AbbVie, a major biopharmaceutical company, is heavily dependent on the life cycle of its key drugs. This chart reflects investor expectations regarding the company's ability to offset the loss of exclusivity for its blockbuster Humira with new drugs. The dynamics demonstrate the market's confidence in the success of AbbVie's R&D and new products.
%20P%2FE%20ABBV&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ABBV&v=1772540324105 "Chart of the company's future (projected) P/E ABBV")
Future (projected) P/E of the market segment - Pharma holding
AbbVie, a biopharmaceutical company known for its blockbuster drug Humira, is actively diversifying its portfolio to reduce its dependence on it. This chart is the market's assessment of the success of this diversification. It compares AbbVie's profit expectations with those of its competitors, showing whether investors have confidence in its new drugs and future growth.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772540324173 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
AbbVie is a biopharmaceutical company known for its blockbuster drug Humira and its active development of a pipeline of new drugs. Its success depends on innovation and patent protection. While the overall market backdrop, visible in this chart, is important, for AbbVie, news from its laboratories plays a key role, as it can redefine the company's prospects regardless of market sentiment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772540324272 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ABBV
AbbVie is a biopharmaceutical company spun out of Abbott Laboratories. Its financial success has long been tied to the blockbuster drug Humira. This chart shows how the company generates profits from its drug portfolio and how successfully it diversifies revenue to offset the loss of exclusivity for its key drugs.
Profit of companies in the market segment - Pharma holding
AbbVie is a biopharmaceutical company whose success was long built on the blockbuster drug Humira. Its story is a shining example of how the life cycle of a single, highly successful drug can shape a company's fate and impact the entire sector. Now, by diversifying its portfolio, AbbVie continues to influence the overall profitability of the pharmaceutical industry through its new developments.
Overall market profit
AbbVie is a biopharmaceutical company known for its immunology and oncology drugs. Its flagship drugs generate billions of dollars in revenue, demonstrating the power of medical innovation to create enormous value. AbbVie's success underscores the importance of the healthcare sector as one of the most profitable and fastest-growing in the modern economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ABBV
AbbVie is a biopharmaceutical company whose revenue has long depended on the blockbuster drug Humira. This chart shows the market's confidence in the ability of new drugs like Skyrizi and Rinvoq to offset the loss of exclusivity for its old hit. Portfolio diversification is a key objective for future profit growth.
%20profit%20of%20the%20company%20ABBV&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ABBV&v=1772540324614 "Graph of future (projected) profit of the company ABBV")
Future (predicted) profit of companies in the market segment - Pharma holding
AbbVie is a biopharmaceutical company known for its blockbuster drug Humira and a strong immunology and oncology portfolio. The chart shows the projected profit trajectory for the entire pharmaceutical industry. This allows one to compare AbbVie's growth prospects from new drugs with analysts' overall expectations for the sector.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772540324673 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
This chart shows expectations for biopharmaceutical company AbbVie, which relies heavily on its blockbuster drug Humira and its successors. The profit forecast reflects how successfully the company can compensate for the loss of exclusivity for its lead drug with new immunology and oncology products. The dynamics are sensitive to product portfolio news.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772540324718 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ABBV
AbbVie is a major biopharmaceutical company whose success was largely dependent on the blockbuster drug Humira. This chart shows how investors value its revenue in the context of patent expirations and the introduction of new drugs. The dynamics of the multiple reflect the market's confidence in the company's ability to offset losses and ensure future growth.
P/S market segment - Pharma holding
AbbVie is a major biopharmaceutical company known for its blockbuster drug Humira and a strong portfolio of immunology and oncology drugs. This chart reflects the average revenue estimate in the pharmaceutical industry. It helps assess how the market perceives the risks associated with patent expirations and the potential of the company's new developments.
P/S of the market as a whole
AbbVie is a biopharmaceutical company heavily dependent on sales of its blockbuster drug Humira and its efforts to diversify its portfolio. Its revenue is a balance between revenue from existing patents and the prospects for new ones. This chart, showing average revenue estimates, helps understand how the market assesses AbbVie's ability to offset the loss of exclusivity for its key drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ABBV
AbbVie is a biopharmaceutical company known for its blockbuster drug Humira. Its future now hinges on the success of new drugs that are expected to replace revenue from its patent-defunct leader. This chart shows how the market is assessing the prospects of the new drug portfolio. It reflects investor confidence in AbbVie's ability to generate future revenue growth.
%20P%2FS%20ABBV&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ABBV&v=1772540324963 "The graph of the company's future (projected) P/S ABBV")
Future (projected) P/S of the market segment - Pharma holding
AbbVie is a biopharmaceutical company known for its blockbuster drug Humira and its active development of a pipeline of new drugs. This chart compares its future sales expectations with those of other pharmaceutical companies. Do investors believe that new products will offset the loss of exclusivity for Humira and drive further growth?
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772540325065 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
AbbVie is a biopharmaceutical company known for its blockbuster drugs, particularly in the immunology field. Its ability to generate consistently high revenue and bring new drugs to market supports investor optimism across the sector. This contributes to the overall positive revenue growth expectations reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772540325214 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ABBV
AbbVie is a biopharmaceutical company known for its immunology and oncology drugs, including the blockbuster Humira. The performance on this chart reflects the commercial success of its drug portfolio and its ability to bring new, in-demand drugs to market, offsetting the loss of patent protection on older ones.
Sales of companies in the market segment - Pharma holding
AbbVie is a biopharmaceutical company focused on developing medicines for complex diseases, particularly in immunology and oncology. Its growth is driven by the success of its flagship drugs and the development of new ones. This chart shows aggregate sales in the pharmaceutical sector, demonstrating the overall market dynamics, where AbbVie competes for leadership in its niches.
Overall market sales
AbbVie is a major biopharmaceutical company known for its blockbuster drugs, particularly in the field of immunology. Its success is built on research and patent protection. This graph, which reflects the overall state of the economy, is indirectly important for AbbVie: it affects government healthcare budgets and patients' ability to afford expensive treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ABBV
AbbVie is a major biopharmaceutical company whose success has long been tied to Humira. Now, future revenue depends on how successfully new drugs can offset the loss of exclusivity for older blockbusters. This chart reflects Wall Street's confidence in the company's pipeline of new products and its ability to generate future growth.
%20sales%20of%20the%20company%20ABBV&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ABBV&v=1772540325546 "Schedule of future (projected) sales of the company ABBV")
Future (projected) sales of companies in the market segment - Pharma holding
AbbVie is a major biopharmaceutical company known for its immunology and oncology drugs. This chart shows the projected total revenue for the entire pharmaceutical sector. It helps investors understand overall growth expectations for the prescription drug market, providing context for assessing the potential of AbbVie's blockbusters and research programs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772540325657 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
AbbVie is a large biopharmaceutical company focused on developing and marketing innovative drugs. Demand for its key drugs is generally inelastic. However, the overall economic situation, reflected in this chart, impacts government healthcare budgets and the ability of insurance systems to cover expensive treatments, which is important for the company's long-term growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772540325701 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ABBV
AbbVie, a biopharmaceutical company spun out of Abbott Laboratories and known for its blockbuster drug Humira, demonstrates how profitable patented drugs can be. The dynamics of this indicator reflect the life cycle of its key drugs and the company's ability to bring new ones to market to offset the expiration of old patents.
Market segment marginality - Pharma holding
AbbVie is a biopharmaceutical company known for its blockbuster drug Humira. Its strategy focuses on developing and acquiring patented drugs in key therapeutic areas, which provides significant pricing power. The data presented illustrates how a successful portfolio of best-selling drugs enables the company to generate profitability above the industry average.
Market marginality as a whole
AbbVie is a biopharmaceutical company known for its blockbusters, particularly Humira. Its business model depends on the life cycle of patents. This chart shows overall profitability. It illustrates AbbVie's pharmaceutical strategy: maximizing profits from successful drugs and continually investing in research to replace those that lose protection.
Employees in the company, segment and market as a whole
Number of employees in the company ABBV
AbbVie is a biopharmaceutical company formed after the split of Abbott Labs, focusing on immunology and oncology. The scale reflected here reflects the size of the team behind the development and commercialization of blockbuster drugs like Humira. Changes in staff may be related to acquisitions to expand the drug portfolio and investments in new research.
Share of the company's employees ABBV within the market segment - Pharma holding
This figure demonstrates AbbVie's standing as a leader in the biopharmaceutical industry. The significant share of highly qualified employees in the sector underscores the company's focus on science-intensive research and the development of complex drugs in areas such as immunology and oncology. This reflects its strength in innovative medicine, measured by talent.
Number of employees in the market segment - Pharma holding
AbbVie is a major biopharmaceutical company focused on developing innovative drugs in areas such as immunology and oncology. Its competitiveness is determined by the quality of its research and development team. This chart illustrates the talent pool in the pharmaceutical industry, where AbbVie is a magnet for world-class scientists.
Number of employees in the market as a whole
AbbVie is a major biopharmaceutical company known for its blockbuster drug Humira and now new immunology and oncology drugs. This graph of total employment shows the state of payers. AbbVie's success depends on the ability of the healthcare system (insurers and governments), financed by contributions from working people, to pay for their expensive and effective drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ABBV (ABBV)
AbbVie is a shining example of how a single blockbuster drug can determine the value of an entire company. The bulk of its market capitalization was long tied to the Humira patent. This chart shows how the market values the intellectual property created by a scientific team, where each researcher's contribution is potentially worth billions.
%20of%20the%20company%20ABBV%20(ABBV)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ABBV-ABBV&v=1772540326206 "Chart of market capitalization per employee (in thousands of dollars) of the company ABBV (ABBV)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
AbbVie is a classic "big pharma," whose value historically depended on the blockbuster drug Humira. Now the focus is on the R&D pipeline. The company's value lies in its patents. This chart shows the market capitalization generated by each employee (primarily R&D and sales), reflecting the market's confidence in the productivity of its laboratories.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772540326438 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
AbbVie is a biopharmaceutical company spun out of Abbott Labs. Its high market capitalization per employee, reflected in the chart, is due to the success of its blockbuster drug, Humira, and other patented drugs. Value is created not by mass labor, but by intellectual property, making each scientist and researcher incredibly valuable to the company.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772540326443 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ABBV (ABBV)
AbbVie is a biopharmaceutical company whose success has long been built on the blockbuster Humira. This chart shows how profitable a model dependent on one or two mega-successful patents is. Every employee, from scientist to representative, is dedicated to monetizing R&D. Now the dynamics reflect the success of the company's portfolio diversification.
%20Chart%20ABBV%20(ABBV)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ABBV-ABBV&v=1772540326475 "Company Profit Per Employee (in thousands of dollars) Chart ABBV (ABBV)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
AbbVie is a biopharmaceutical company. This chart shows the average for the pharmaceutical industry. This sector thrives on R&D and patents. The average return on personnel is high here, as a single successful blockbuster drug (like Humira) can generate tens of billions, covering all the costs of staffing scientists and marketers.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772540326578 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
AbbVie is a biopharmaceutical company known for its blockbuster drugs like Humira. Its business model is a shining example of how a single successful patent can generate tens of billions of dollars. This chart illustrates how highly rewarding employees can be in an industry where intellectual property is the most valuable asset.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772540326636 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ABBV (ABBV)
AbbVie is a biopharmaceutical company focused on developing and commercializing innovative drugs. This chart illustrates a business model built on blockbusters like Humira. A small team of scientists and marketers can generate billions of dollars in revenue from a single successful patent, resulting in superior performance.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ABBV-ABBV&v=1772540326778 "Sales chart per company employee ABBV (ABBV)")
Sales per employee in the market segment - Pharma holding
AbbVie is a biopharmaceutical company focused on immunology, oncology, and other complex diseases. This chart compares revenue per employee to the segment average. It helps assess how productive their R&D investments are and how effectively their commercial teams are delivering blockbusters compared to competitors.
Sales per employee for the market as a whole
AbbVie is a biopharmaceutical company best known for its blockbuster drug Humira. Like Eli Lilly, their business is R&D and patents. This metric demonstrates how one or a few highly successful drugs can account for the lion's share of revenue, making the average contribution of each employee (especially in R&D and marketing) very high compared to other industries.
Short shares by company, segment and market as a whole
Shares shorted by company ABBV (ABBV)
AbbVie is a pharmaceutical company known for its blockbuster drug Humira (an arthritis treatment). This chart reflects serious market concerns. The main risk that bears are betting on is the "patent cliff." Humira is losing exclusivity, and the company must prove that its new drugs can offset the inevitable revenue decline from its former leader.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ABBV-ABBV&v=1772540326969 "Short Shares Chart for the Company ABBV (ABBV)")
Shares shorted by market segment - Pharma holding
AbbVie, spun off from Abbott, became a giant thanks to the blockbuster drug Humira. Now the company is actively diversifying its portfolio into oncology and neuroscience. This chart shows the general sentiment toward "big pharma." It reflects the combined bets that the sector will face a "patent cliff" or increased generic competition.
Shares shorted by the overall market
AbbVie is a pharmaceutical company known for its blockbuster drug Humira and a strong pipeline of new drugs. Like many pharmaceutical companies, it is considered defensive. This chart shows the overall level of pessimism. During periods of market turmoil, investors often shift to sectors with stable demand, and AbbVie, with its strong cash flows from life-saving drugs, attracts capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ABBV (ABBV)
AbbVie, a major pharmaceutical company, relied heavily on its blockbuster drug Humira, which faced competition from biosimilars. This oscillator, above 70, may reflect success in portfolio diversification. A drop below 30 often signals concerns about the rate of revenue erosion from Humira or failures in new drug development.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ABBV-ABBV&v=1772540327323 "RSI 14 indicator chart for the company's stock ABBV (ABBV)")
RSI 14 Market Segment - Pharma holding
AbbVie (ABBV) is a pharmaceutical company whose fate was tied to the blockbuster drug Humira. Their main challenge now is to prove to the market that they can grow after the "patent collapse." This metric measures the "temperature" of the entire pharmaceutical sector. It helps us understand whether ABBV is oversold due to its unique patent risks or whether there is a general cooling off in the industry as a whole.
RSI 14 for the overall market
AbbVie, known for its blockbuster Humira, is successfully diversifying its portfolio with new drugs in immunology and oncology. Pharmaceuticals are often considered a defensive sector. This indicator shows when the overall market is overheated or undercooled, allowing investors to assess how closely the market sentiment aligns with the company's fundamental success.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ABBV (ABBV)
For AbbVie, this chart shows how analysts assess "life after Humira." Their price targets depend entirely on whether new drugs (Skyrizi, Rinvoq) can offset the revenue loss from the world's best-selling drug. Wall Street's forecast is a bet that the company's pipeline of new blockbusters and recent acquisitions (ImmunoGen) will allow it to avoid the patent cliff.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ABBV-ABBV&v=1772540327622 "A chart showing analyst consensus forecasts for the expected stock price. ABBV (ABBV)")
The difference between the consensus estimate and the actual stock price ABBV (ABBV)
AbbVie is a biopharmaceutical company known for its blockbuster drug Humira and is actively developing a new generation of immunology and oncology drugs. This chart shows the difference between the current price and the average target price. It reflects how well analysts believe the company is managing the patent cliff for Humira and whether they see growth potential in its new products.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ABBV-ABBV&v=1772540327718 "A chart showing the difference between the consensus forecast and the actual stock price. ABBV (ABBV)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
AbbVie, a biopharmaceutical company known for its blockbuster drug Humira, is now actively seeking new growth drivers in oncology and immunology. This chart reflects analysts' general opinion on the outlook for the entire pharmaceutical sector. It shows whether experts see potential in new drugs in the industry or fear "patent cliffs."
Analysts' consensus forecast for the overall market share price
AbbVie is a biopharmaceutical giant known for its blockbuster Humira and now new drugs. Healthcare is considered a defensive sector. This chart shows the overall market consensus, helping to understand the market's current phase. In a bullish rally, AbbVie may lag, but in a bearish one (a falling chart), its stable revenues become a safe haven.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ABBV
AbbVie is a major pharmaceutical company whose fortune has been built for years on the mega-blockbuster Humira. Now, their main challenge is surviving the patent cliff. This chart reflects the market's assessment of this race: whether their new oncology and immunology drugs will be able to offset the loss of revenue from their former flagship.
AKIMA Market Segment Index - Pharma holding
AbbVie is a biopharmaceutical company known for its blockbuster drug Humira and actively developing new drugs in immunology and oncology. This comprehensive metric evaluates R&D. The graph shows the average value for the segment. This benchmark helps us understand how AbbVie's drug portfolio enables it to be more effective than the average pharmaceutical company.
The AKIM Index for the overall market
AbbVie is a biopharmaceutical company whose success was largely built on the blockbuster drug Humira. The company is currently actively diversifying its portfolio, developing new drugs in immunology and oncology. This chart, showing the average market share, is important for context. It allows one to assess how AbbVie, as it navigates the patent cliff, compares to the overall market situation affecting the healthcare sector.
